Latest Earnings Results: Q3 '26
Estimated EPS
-$0.52
Reported EPS
-$0.52
Surprise
+0.64%
Estimated Rev
$34.72M
Reported Rev
$35.51M
Surprise
+2.26%
• Reported GAAP EPS of -$0.52 down -57.58% YoY • Reported revenue of $35.51M up 30.31% YoY • Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.
Bullish Takeaway
Beta Bionics reported Q3 2026 net sales of $35.5M and PBP channel sales up 118%, received FDA clearance for Mint, completed type 2 pivotal-trial enrollment, and announced an Eversense integration agreement.
Bearish Takeaway
Beta Bionics reported larger operating losses, withdrew 3D Intelligences 510(k) application for additional simulator validation, and cited potential Q4 2026 revenue deferrals of up to $8.5M as prospective iLet users could await Mint.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.50 | -- | -- | N/A |
Q3 '26 | -$0.52 | -$0.52 | 0.64% | BEAT |
Q2 '26 | -$0.58 | -$0.53 | 8.78% | BEAT |
Q1 '26 | -$0.50 | -$0.49 | 2.53% | BEAT |
Q4 '25 | -$0.40 | -$0.30 | 25.59% | BEAT |